{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:40:49Z","timestamp":1787020849998,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A recent randomised controlled trial failed to demonstrate a beneficial effect of recombinant human thrombomodulin (rhTM) on sepsis. However, there is still controversy in the effects of rhTM for sepsis due to the heterogeneity of the study population. We previously identified patients with a distinct phenotype that could be a potential target of rhTM therapy (rhTM target phenotype). However, for application in the clinical setting, a simple tool for determining this target is necessary. Thus, using three multicentre sepsis registries, we aimed to develop and validate a machine learning model for predicting presence of the target phenotype that we previously identified for targeted rhTM therapy. The predictors were platelet count, PT-INR, fibrinogen, fibrinogen\/fibrin degradation products, and D-dimer. We also implemented the model as a web-based application. Two of the three registries were used for model development (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20093694), and the remaining registry was used for validation (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20091184). Approximately 8\u20139% of patients had the rhTM target phenotype in each cohort. In the validation, the C statistic of the developed model for predicting the rhTM target phenotype was 0.996 (95% CI 0.993\u20130.998), with a sensitivity of 0.991 and a specificity of 0.967. Among patients who were predicted to have the potential target phenotype (predicted target patients) in the validation cohort (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009142), rhTM use was associated with a lower in-hospital mortality (adjusted risk difference,\u2009\u2212\u200931.3% [\u2212\u200953.5 to\u2009\u2212\u20099.1%]). The developed model was able to accurately predict the rhTM target phenotype. The model, which is available as a web-based application, could profoundly benefit clinicians and researchers investigating the heterogeneity in the treatment effects of rhTM and its mechanisms.\n                  <\/jats:p>","DOI":"10.1186\/s13054-022-04020-1","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T09:03:47Z","timestamp":1652951027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Web-based application for predicting the potential target phenotype for recombinant human thrombomodulin therapy in patients with sepsis: analysis of three multicentre registries"],"prefix":"10.1186","volume":"26","author":[{"given":"Tadahiro","family":"Goto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Uchimido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mineji","family":"Hayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Kushimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"issue":"4","key":"4020_CR1","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/jth.12841","volume":"13","author":"K Yamakawa","year":"2015","unstructured":"Yamakawa K, Aihara M, Ogura H, Yuhara H, Hamasaki T, Shimazu T. Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis. J Thromb Haemost. 2015;13(4):508\u201319.","journal-title":"J Thromb Haemost"},{"issue":"20","key":"4020_CR2","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2019.5358","volume":"321","author":"JL Vincent","year":"2019","unstructured":"Vincent JL, Francois B, Zabolotskikh I, Daga MK, Lascarrou JB, Kirov MY, Pettila V, Wittebole X, Meziani F, Mercier E, et al. Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: The SCARLET Randomized Clinical Trial. JAMA. 2019;321(20):1993\u20132002.","journal-title":"JAMA"},{"issue":"1","key":"4020_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13054-019-2587-2","volume":"23","author":"K Yamakawa","year":"2019","unstructured":"Yamakawa K, Levy JH, Iba T. Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis. Crit Care. 2019;23(1):302.","journal-title":"Crit Care"},{"issue":"22","key":"4020_CR4","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1001\/jama.2021.20552","volume":"326","author":"DC Angus","year":"2021","unstructured":"Angus DC, Chang CH. Heterogeneity of treatment effect: estimating how the effects of interventions vary across individuals. JAMA. 2021;326(22):2312\u20133.","journal-title":"JAMA"},{"issue":"20","key":"4020_CR5","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1001\/jama.2019.5791","volume":"321","author":"CW Seymour","year":"2019","unstructured":"Seymour CW, Kennedy JN, Wang S, Chang CH, Elliott CF, Xu Z, Berry S, Clermont G, Cooper G, Gomez H, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003\u201317.","journal-title":"JAMA"},{"issue":"2","key":"4020_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1007\/s00134-021-06587-9","volume":"48","author":"A Granholm","year":"2022","unstructured":"Granholm A, Alhazzani W, Derde LPG, Angus DC, Zampieri FG, Hammond NE, Sweeney RM, Myatra SN, Azoulay E, Rowan K, et al. Randomised clinical trials in critical care: past, present and future. Intensive Care Med. 2022;48(2):164\u201378.","journal-title":"Intensive Care Med"},{"issue":"1","key":"4020_CR7","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13054-021-03541-5","volume":"25","author":"D Kudo","year":"2021","unstructured":"Kudo D, Goto T, Uchimido R, Hayakawa M, Yamakawa K, Abe T, Shiraishi A, Kushimoto S. Coagulation phenotypes in sepsis and effects of recombinant human thrombomodulin: an analysis of three multicentre observational studies. Crit Care. 2021;25(1):114.","journal-title":"Crit Care"},{"issue":"1","key":"4020_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s13054-016-1415-1","volume":"20","author":"K Yamakawa","year":"2016","unstructured":"Yamakawa K, Umemura Y, Hayakawa M, Kudo D, Sanui M, Takahashi H, Yoshikawa Y, Hamasaki T, Fujimi S, Japan Septic Disseminated Intravascular Coagulation Study G. Benefit profile of anticoagulant therapy in sepsis: a nationwide multicentre registry in Japan. Crit Care. 2016;20(1):229.","journal-title":"Crit Care"},{"issue":"8","key":"4020_CR9","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1097\/CCM.0000000000004426","volume":"48","author":"M Levi","year":"2020","unstructured":"Levi M, Vincent JL, Tanaka K, Radford AH, Kayanoki T, Fineberg DA, Hoppensteadt D, Fareed J. Effect of a recombinant human soluble thrombomodulin on baseline coagulation biomarker levels and mortality outcome in patients with sepsis-associated coagulopathy. Crit Care Med. 2020;48(8):1140\u20137.","journal-title":"Crit Care Med"},{"key":"4020_CR10","doi-asserted-by":"publisher","first-page":"101257","DOI":"10.1016\/j.eclinm.2021.101257","volume":"43","author":"M Fujiogi","year":"2022","unstructured":"Fujiogi M, Dumas O, Hasegawa K, Jartti T, Camargo CA. Identifying and predicting severe bronchiolitis profiles at high risk for developing asthma: analysis of three prospective cohorts. EClinicalMedicine. 2022;43:101257.","journal-title":"EClinicalMedicine"},{"key":"4020_CR11","doi-asserted-by":"publisher","first-page":"180243","DOI":"10.1038\/sdata.2018.243","volume":"5","author":"M Hayakawa","year":"2018","unstructured":"Hayakawa M, Yamakawa K, Saito S, Uchino S, Kudo D, Iizuka Y, Sanui M, Takimoto K, Mayumi T. Nationwide registry of sepsis patients in Japan focused on disseminated intravascular coagulation 2011\u20132013. Sci Data. 2018;5:180243.","journal-title":"Sci Data"},{"key":"4020_CR12","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.jcrc.2018.03.011","volume":"45","author":"D Kudo","year":"2018","unstructured":"Kudo D, Kushimoto S, Miyagawa N, Sato T, Hasegawa M, Ito F, Yamanouchi S, Honda H, Andoh K, Furukawa H, et al. The impact of organ dysfunctions on mortality in patients with severe sepsis: a multicenter prospective observational study. J Crit Care. 2018;45:178\u201383.","journal-title":"J Crit Care"},{"issue":"1","key":"4020_CR13","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s13054-018-2186-7","volume":"22","author":"T Abe","year":"2018","unstructured":"Abe T, Ogura H, Shiraishi A, Kushimoto S, Saitoh D, Fujishima S, Mayumi T, Shiino Y, Nakada TA, Tarui T, et al. Characteristics, management, and in-hospital mortality among patients with severe sepsis in intensive care units in Japan: the FORECAST study. Crit Care. 2018;22(1):322.","journal-title":"Crit Care"},{"issue":"2","key":"4020_CR14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","volume":"41","author":"RP Dellinger","year":"2013","unstructured":"Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580\u2013637.","journal-title":"Crit Care Med"},{"issue":"4","key":"4020_CR15","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1097\/01.CCM.0000050454.01978.3B","volume":"31","author":"MM Levy","year":"2003","unstructured":"Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, et al. 2001 SCCM\/ESICM\/ACCP\/ATS\/SIS international sepsis definitions conference. Crit Care Med. 2003;31(4):1250\u20136.","journal-title":"Crit Care Med"},{"issue":"1","key":"4020_CR16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1093\/bioinformatics\/btr597","volume":"28","author":"DJ Stekhoven","year":"2012","unstructured":"Stekhoven DJ, Buhlmann P. MissForest\u2013non-parametric missing value imputation for mixed-type data. Bioinformatics. 2012;28(1):112\u20138.","journal-title":"Bioinformatics"},{"key":"4020_CR17","doi-asserted-by":"publisher","first-page":"m441","DOI":"10.1136\/bmj.m441","volume":"368","author":"RD Riley","year":"2020","unstructured":"Riley RD, Ensor J, Snell KIE, Harrell FE Jr, Martin GP, Reitsma JB, Moons KGM, Collins G, van Smeden M. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441.","journal-title":"BMJ"},{"issue":"15","key":"4020_CR18","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","volume":"286","author":"BL Warren","year":"2001","unstructured":"Warren BL, Eid A, Singer P, Pillay SS, Carl P, Novak I, Chalupa P, Atherstone A, Penzes I, Kubler A, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA. 2001;286(15):1869\u201378.","journal-title":"JAMA"},{"issue":"22","key":"4020_CR19","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","volume":"366","author":"VM Ranieri","year":"2012","unstructured":"Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med. 2012;366(22):2055\u201364.","journal-title":"N Engl J Med"},{"key":"4020_CR20","doi-asserted-by":"publisher","first-page":"h5651","DOI":"10.1136\/bmj.h5651","volume":"351","author":"JF Burke","year":"2015","unstructured":"Burke JF, Sussman JB, Kent DM, Hayward RA. Three simple rules to ensure reasonably credible subgroup analyses. BMJ. 2015;351:h5651.","journal-title":"BMJ"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-022-04020-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-022-04020-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T09:12:47Z","timestamp":1652951567000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-022-04020-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4020"],"URL":"https:\/\/doi.org\/10.1186\/s13054-022-04020-1","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The three original studies were approved, and the need for informed consent was waived by the institutional review boards at the participating hospitals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DK, MH, and SK received personal fees from Asahi Kasei Pharma Corporation. TG is the Chief Scientific Officer at TXP Medical Co. Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"145"}}